The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
After several cancer failures Celldex tries its hand at autoimmune disease, and the market likes it.
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
The first look at Turning Point’s TPX-0022 shows signs of activity beyond cMet inhibitors’ proven use in lung cancer.